Therapeutics

ABT 418

Tools

Back to the Top

Overview

Name: ABT 418
Chemical Name: 3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole
Therapy Type: Small Molecule
Target Type: Cholinergic System
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Discontinued)
Approved for: None

Background

Acute administration of nicotine to AD patients improved accuracy of delayed recall, as well as deficits in attention and information processing (Sahakian et al. 1989; Wesnes and Warburton, 1984; Jones et al, 1992). However, nictoine has significant side effects including tachycardia, elevated blood pressure, and gastrointestinal distress.  Agonists with better selectivity for nAChR subtypes that mediate the beneficial effects could be useful. ABT-418 is a novel bioisostere of (-)-nicotine. Like nicotine, it is an agonist for nicotinic acetylcholine receptors (nAChRs),  ionotropic  receptors composed of five subunits arranged around a central pore. It is unclear which nicotinic receptor subtypes are preferentially activated by ABT-418. 

Comments

Make a Comment

To make a comment you must login or register.

Comments on this content

No Available Comments

References

Paper Citations

  1. . The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry. 1989 Jun;154:797-800. PubMed.
  2. . Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology (Berl). 1984;82(3):147-50. PubMed.
  3. . Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl). 1992;108(4):485-94. PubMed.

Further Reading

No Available Further Reading